TOKYO & HILVERSUM, Netherlands & OSLO, Norway & MANNHEIM, Germany–(BUSINESS WIRE)–NEC Corporation (NEC, TOKYO: 6701) announced in 2019 that it would expand the application of its cutting-edge AI technologies to drug development, focusing on advanced therapy as part of enhancing its healthcare business. Subsequently, in order to advance AI-powered personalized treatment and beyond, NEC acquired Norway-based NEC OncoImmunity (NOI) that same year.
Today, NEC and NOI announced that NOI will be realigned as a subsidiary of NEC Bio B.V. (NB) in Hilversum, Netherlands, a newly established wholly owned subsidiary of NEC. At the same time, NEC established another new company, NEC Bio Therapeutics (NBT) in Mannheim, Germany, also a subsidiary of NB.
The new structure will enable NEC to drive long-term growth. The main focus of NB will be to streamline all AI, drug research and development activities. While NOI will continue with its research activities, working on the frontiers of the intersection between drug research and AI technology, NBT will lead the clinical development and clinical strategy of the assets in the drug development pipeline.
NEC Bio, along with NOI and NBT, will continue to work with various partners to facilitate pre-clinical and clinical development in the infectious disease and oncology fields.
Contacts
Joseph Jasper
j-jasper(at)nec.com
Hamburger SV face Borussia Mönchengladbach on Friday 6 November in a Bundesliga relegation six-pointer between…
The most unsettling thing about Dead-End Job isn't the monster behind the basement door. It's…
Netflix has released the official trailer for The Further Mis-Adventures of Cliff Booth, revealing a…
Thomas Markle Sr., the estranged father of Meghan Markle, was arrested on Friday, November 6,…
Eastern Storm face Dolphins on November 6 in the 65th match of the YesPlay Pro20…
300 entities onboarded in first nine monthsThe Unique Identification Authority of India (UIDAI) has brought…